

Autoimmune Disorder

## An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03202368 2016-002716-41  
ML39425

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a multicenter, interventional, open-label, long-term extension study of Study WA28119 (NCT01791153) to evaluate the long-term safety of SC tocilizumab in participants with GCA who subsequently have flare or persisting disease activity. A maximum of 11 participants from six centers in France that participated in the WA28119 study will be enrolled. The entire study duration is anticipated to be approximately 160 weeks.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

**NCT03202368 2016-002716-41 ML39425**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 50 Years

**Healthy Volunteers**  
No